SPOTLIGHT: King asks FDA to block ZymoGenetics' drug

King Pharmaceuticals has petitioned the FDA not to approved ZymoGenetics' rThrombin, a treatment for surgical bleeding. King claims that ZymoGenetics' drug has not been sufficiently tested and that it poses a risk to the public if approved. Why is King so interested? Well, because the company makes a competing version of the drug and stands to lose market share if a new version of the product is approved. If the FDA takes the request into account, it could be a major setback for ZymoGenetics. Report